A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
about
New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancinMethicillin-resistant Staphylococcus aureus therapy: past, present, and futureAntimicrobial proteins in intestine and inflammatory bowel diseasesEugenol: a phyto-compound effective against methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical strain biofilmsAntibiotics in the clinical pipeline at the end of 2015.Complete genome sequence and comparative genomic analyses of the vancomycin-producing Amycolatopsis orientalis.Newer antibacterials in therapy and clinical trialsTelavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infectionsAntibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Binaphthyl-anchored antibacterial tripeptide derivatives with hydrophobic C-terminal amino acid variations.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infectionsChemical tailoring of teicoplanin with site-selective reactionsThe potential of antimicrobial peptides as biocides.Industrial natural product chemistry for drug discovery and development.Glycopeptide antibiotics: back to the future.Current and emerging drugs for acute bacterial skin and skin structure infections: an update.Natural product and natural product derived drugs in clinical trials.Oritavancin: A Long-Half-Life Lipoglycopeptide.Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.In-vitro antimicrobial activity of marine actinobacteria against multidrug resistance Staphylococcus aureus.Actinomycetes: still a source of novel antibiotics.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?Eremomycin pyrrolidide: a novel semisynthetic glycopeptide with improved chemotherapeutic properties
P2860
Q26764885-6F2C16E7-2662-4698-A825-192DC2CCEFFCQ27011165-A390E374-52A7-4CE3-9628-F525E2423810Q27023239-3D64B1E5-AE86-40ED-9BD9-E47BAB26559DQ28544466-5741553E-6C74-47A3-B8E7-8A1BD2EAB83DQ30249262-C65DDA62-4A3C-47EA-A64D-1C7141F7717EQ33722342-17110C19-D737-48E2-80A7-E5B3463309D7Q34488329-619E2EBC-96FD-4AF0-8F9E-29533CAE2392Q35026607-C44C5CB9-A29D-40EF-A0D2-6E1B527E6E85Q35542062-F95FB393-05F7-495C-8697-3ACD39BE66E9Q36281200-2C6B3868-8565-49D6-A5F0-173AE5E66B00Q36393640-AA95A42C-D43D-476D-9BE1-08A6BCCD3342Q37238862-08907688-503C-4265-A043-C59F8E5D84CBQ37954604-2E28349E-6217-4A84-90F0-28CFE9F8B1FDQ38154186-D4221CB3-5B84-4D15-97E3-F83EE7C1ED9AQ38239460-A8B21C36-13D7-4933-8518-5E5BC8B2A185Q38242081-BD4B256D-F9FA-405E-9EC5-6B5D8EBE3D43Q38247457-AA192363-087A-428A-842C-2CBDD4C05B54Q38434265-5AB6FCF1-A4BF-46CC-831D-CDF90E979E04Q38536284-5FBB6773-F1B0-4320-B98F-4FF3CB1665EDQ38545589-7A01967B-5871-4AFE-B0FF-069A67CC414EQ38575717-C3765340-CA71-489D-8B79-0FD5C93389D9Q39164161-572EE294-0AB5-42F6-B4BB-5848455F9EC8Q39336538-40CD492C-7CF4-4714-A4A6-8D60C9B00724Q46319269-FA7FC951-1C17-4890-ABB1-27856E33D778Q48197188-3A779EDC-4FB5-4DCE-B646-AC8559F2A94CQ52655525-2102FDA2-5579-4DF9-AF71-CA6B11398956Q58754588-E1A9B666-CA10-4138-B879-8FAC23428009
P2860
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
@en
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
@nl
type
label
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
@en
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
@nl
prefLabel
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
@en
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
@nl
P2860
P356
P1433
P1476
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
@en
P2093
Brian T Tsuji
Michael T Guskey
P2860
P356
10.1592/PHCO.30.1.80
P407
P577
2010-01-01T00:00:00Z